Ionis Pharmaceuticals, Inc. (IONS)
After hours:
| Previous Close | 41.02 |
| Open | 41.02 |
| Bid | 42.15 x 100 |
| Ask | 42.21 x 300 |
| Day's Range | 41.02 - 42.86 |
| 52 Week Range | 35.95 - 54.44 |
| Volume | |
| Avg. Volume | 1,574,398 |
| Market Cap | 6.654B |
| Beta (5Y Monthly) | 0.39 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.52 |
| Earnings Date | Oct 31, 2024 - Nov 04, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 62.13 |
ZacksIonis Stock Drops 12% on Pricing of $500M Common Stock Offering
IONS' shares fell after announcing the pricing of its secondary issue of shares, which were at a 12% discount to the previous closing price.
PR NewswireIonis announces pricing of $500.3 million public offering
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the pricing of an underwritten public offering of 11,500,000 shares of its common stock. The shares of common stock are being sold at a public offering price of $43.50 per share. The aggregate gross proceeds to Ionis from this offering are expected to be approximately $500.3 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Ionis. Ionis has granted the underwriters a 30-day
- PR Newswire
Ionis announces proposed public offering of common stock
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced a proposed underwritten public offering of $500.0 million of its common stock. Ionis intends to grant the underwriters a 30-day option to purchase up to an additional $75.0 million of shares of its common stock offered in the public offering on the same terms and conditions. Ionis intends to use the net proceeds from the offering to fund its independent commercial launches, late-stage clinical programs, earlier pipeline programs, and res
